Log In Sign up
The largest database of trusted experimental protocols

Ml rr s2 cda

Manufactured by MedChemExpress
Visit Supplier
Sourced in United Kingdom

The ML RR-S2 CDA is a compact centrifuge designed for efficient sample separation. It features a microprocessor-controlled system for accurate speed and time settings, as well as a robust construction for reliable operation. The core function of this equipment is to rapidly separate components in liquid samples through centrifugal force.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd40 clone fgk4, by BioXCell (1 mentions) Sarrp 200, by Xstrahl (1 mentions) Penicillin, by Thermo Fisher Scientific (1 mentions) Streptomycin, by Thermo Fisher Scientific (1 mentions) Rpmi 1640, by Thermo Fisher Scientific (1 mentions) Glutamax, by Thermo Fisher Scientific (1 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (1 mentions) Non essential amino acids (neaa), by Thermo Fisher Scientific (1 mentions)

Close spelling variants of this product

ML-RR-S2 CDA (ADU-S100) (2 citations)

3 protocols using ml rr s2 cda

1

Combination Immunotherapy and Radiation for Pancreatic Cancer

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice received 30 μg of Flt3L (CDX-301, Celldex) i.p. every day for 9 days as previously published (Salmon et al., 2016 (link)). Mice received 100 μg of anti-CD40 (clone FGK4.5, BioXCell) i.p. every 5 days starting concurrent with other treatment upon palpation and 1st ultrasound measure. Certain mice received 25 μg of STING agonist (ML-RR-S2 CDA, MedChemExpress) intratumorally every 4 days starting concurrent with other treatment upon palpation and 1st ultrasound measure.
Mice received Radiation (RT) as three daily fractionated doses (8 Gy x 3) using the Small Animal Radiation Research Platform (SARRP200, XStrahl Life Sciences). Mice were injected i.p. with an iodine contrast agent (2100 mg/kg) before being placed on the irradiation platform one at a time under isoflurane anesthesia. Conebeam computed tomography (CT) imaging was performed for each individual mouse to pinpoint the pancreas, images were imported into Muriplan and used to select an isocenter. The tumor was then irradiated using anterior-posterior-opposed beams using the 10mm x 10mm collimator at a dose rate of 3.9 Gy/min. Mice were monitored over 2 weeks for signs of radiation sickness or weight-loss. DietGel recovery gel was provided for 14 day window immediately following radiation therapy in survival studies.
Hegde S., Krisnawan V.E., Herzog B.H., Zuo C., Breden M.A., Knolhoff B.L., Hogg G.D., Tang J.P., Baer J.M., Mpoy C., Lee K.B., Alexander K.A., Rogers B.E., Murphy K.M., Hawkins W.G., Fields R.C., DeSelm C.J., Schwarz J.K, & DeNardo D.G. (2020). Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer cell, 37(3), 289-307.e9.
+ Open protocol
+ Expand
2

Synergistic STING and cyto-IL-15 therapy

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
The STING-activating cyclic dinucleotide agonist ADU-S100 (MIW815; ML RR-S2 CDA) (MedChemExpress, Cambridge Bioscience Limited, Cambridge, UK) was diluted in HBSS (Hank’s balanced salt solution, vehicle) and was used at 50 µg (in 50µl) doses. IL-15 and cytotopically modified (cyto-IL-15) were produced in our laboratory as previously described (24 (link)), diluted in PBS and were used at 10 µg doses. Cyto-IL-15 is a version of IL-15 conjugated with a bis-myristoylated peptide to allow anchoring of IL-15 to cell membranes, which is in addition to IL-15 receptors binding. Currently a patent has been filled (P71020GB: KCL ref. 501/3048) for the combination of cyto-IL-15 with STING agonists in cancer treatment.
Papaevangelou E., Esteves A.M., Dasgupta P, & Galustian C. (2023). Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models. Frontiers in Immunology, 14, 1196829.
+ Open protocol
+ Expand
3

HNSCC Cell Line Characterization and STING Agonist Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols
Experiments were conducted in seven human HNSCC cell lines of both negative and positive HPV status obtained from ATCC and authenticated by short tandem repeat (STR) profiling. They were routinely checked for Mycoplasma contamination by qPCR. UM-SCC-1 (RRID:CVCL_7707), UM-SCC-11B (RRID:CVCL_7716), UM-SCC-81B (RRID:CVCL_7784) (HPV−), UM-SCC-47 (RRID:CVCL_7759) and UPCI:SCC-090 (RRID:CVCL_1899) (HPV+) were cultured in DMEM supplemented with GlutaMAX (Gibco), 10% FBS (Invitrogen), and 1x nonessential amino acids (NEAA; Gibco). FaDu (RRID:CVCL_1218; HPV−) and UPCI:SCC-154 (RRID:CVCL_2230; HPV+) cells were cultured in modified Eagle's medium (MEM; Gibco) supplemented with GlutaMAX (Gibco), 10% FBS, 1x NEAA, and 3% sodium bicarbonate (Gibco). HeLa (RRID:CVCL_0030) and human monocytic THP-1 (RRID:CVCL_0006) were used as control cell lines and were cultured in DMEM and RPMI1640 media (Gibco) supplemented with 10% FBS and 100 U/mL of penicillin and 100 µg/mL streptomycin (Gibco), respectively. All cells were cultured at 37°C in a 5% CO2 humidified incubator and passaged three to five times between thawing and use in the described experiments. The STING agonist ML RR-S2 CDA (CDA; MedChemExpress, catalog no. HY-12885) was used at indicated concentrations.
Saulters E.L., Kennedy P.T., Carter R.J., Alsufyani A., Jones T.M., Woolley J.F, & Dahal L.N. (2024). Differential Regulation of the STING Pathway in Human Papillomavirus–Positive and -Negative Head and Neck Cancers. Cancer Research Communications, 4(1), 118-133.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!